Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 (Dose Escalation)/Phase 2 (Expansion Cohort) Trial of TY101 as a Single Agent in Patients With Locally Advanced/Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

NCT04458389 is registered in ClinicalTrials.gov with Tayu Huaxia Biotech Medical Group Co., Ltd. as lead sponsor.

NCT NCT04458389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 (Dose Escalation)/Phase 2 (Expansion Cohort) Trial of TY101 as a Single Agent in Patients With Locally Advanced/Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Lead sponsor
Tayu Huaxia Biotech Medical Group Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 7, 2020
Completion date
July 31, 2025
Enrollment
268 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced /metastatic solid tumors, relapsed or refractory lymphomas